Zacks Research Downgrades CSL (OTCMKTS:CSLLY) to Strong Sell

CSL (OTCMKTS:CSLLY) was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a note issued to investors on Tuesday,Zacks.com reports.

Separately, Canaccord Genuity Group raised shares of CSL from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 28th. Two research analysts have rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, CSL has an average rating of “Buy”.

CSL Trading Down 0.7%

OTCMKTS CSLLY traded down $0.42 on Tuesday, hitting $57.59. 26,718 shares of the stock were exchanged, compared to its average volume of 106,865. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.12 and a current ratio of 2.46. The business’s fifty day moving average is $64.57 and its 200 day moving average is $74.10. CSL has a 52 week low of $54.10 and a 52 week high of $94.98.

About CSL

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.